BALAXI PHARMACEUTICALS LIMITED (BALAXI) - Net Assets
Based on the latest financial reports, BALAXI PHARMACEUTICALS LIMITED (BALAXI) has net assets worth Rs2.38 Billion INR (≈ $25.74 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs3.22 Billion ≈ $34.87 Million USD) and total liabilities (Rs844.30 Million ≈ $9.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BALAXI PHARMACEUTICALS LIMITED (BALAXI) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs2.38 Billion |
| % of Total Assets | 73.82% |
| Annual Growth Rate | 61.21% |
| 5-Year Change | 256.63% |
| 10-Year Change | 735869.85% |
| Growth Volatility | 2027.58 |
BALAXI PHARMACEUTICALS LIMITED - Net Assets Trend (2013–2025)
This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's net assets have evolved over time, based on quarterly financial data. Also explore BALAXI PHARMACEUTICALS LIMITED total assets for the complete picture of this company's asset base.
Annual Net Assets for BALAXI PHARMACEUTICALS LIMITED (2013–2025)
The table below shows the annual net assets of BALAXI PHARMACEUTICALS LIMITED from 2013 to 2025. For live valuation and market cap data, see BALAXI market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs2.32 Billion ≈ $25.06 Million |
+15.08% |
| 2024-03-31 | Rs2.01 Billion ≈ $21.78 Million |
+10.11% |
| 2023-03-31 | Rs1.83 Billion ≈ $19.78 Million |
+61.61% |
| 2022-03-31 | Rs1.13 Billion ≈ $12.24 Million |
+74.15% |
| 2021-03-31 | Rs649.80 Million ≈ $7.03 Million |
+134.20% |
| 2020-03-31 | Rs277.46 Million ≈ $3.00 Million |
+688.12% |
| 2019-03-31 | Rs35.21 Million ≈ $380.73K |
+126.46% |
| 2018-03-31 | Rs15.55 Million ≈ $168.13K |
-34.10% |
| 2017-03-31 | Rs23.59 Million ≈ $255.13K |
+7392.46% |
| 2016-03-31 | Rs314.87K ≈ $3.41K |
-2.35% |
| 2015-03-31 | Rs322.45K ≈ $3.49K |
-95.86% |
| 2014-03-31 | Rs7.80 Million ≈ $84.33K |
+3.67% |
| 2013-03-31 | Rs7.52 Million ≈ $81.34K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BALAXI PHARMACEUTICALS LIMITED's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 605186.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs1.63 Billion | 70.54% |
| Common Stock | Rs110.42 Million | 4.76% |
| Other Components | Rs572.23 Million | 24.69% |
| Total Equity | Rs2.32 Billion | 100.00% |
BALAXI PHARMACEUTICALS LIMITED Competitors by Market Cap
The table below lists competitors of BALAXI PHARMACEUTICALS LIMITED ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ree Automotive Holding Inc
NASDAQ:REE
|
$15.90 Million |
|
CLEANTEK Industries Inc
V:CTEK
|
$15.90 Million |
|
Pure Resources Ltd
AU:PR1
|
$15.91 Million |
|
N.C. Housing Public Company Limited
BK:NCH
|
$15.91 Million |
|
Dgenx Co. Ltd
KQ:113810
|
$15.90 Million |
|
Nature Wood Group Limited American Depositary Shares
NASDAQ:NWGL
|
$15.89 Million |
|
MODERN COMMERCE SA ZY-10
F:8F4
|
$15.88 Million |
|
African Media Entertainment
JSE:AME
|
$15.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BALAXI PHARMACEUTICALS LIMITED's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,013,639,000 to 2,317,363,000, a change of 303,724,000 (15.1%).
- Net income of 250,702,000 contributed positively to equity growth.
- Share repurchases of 27,045,000 reduced equity.
- New share issuances of 27,045,000 increased equity.
- Other comprehensive income decreased equity by 37,728,000.
- Other factors increased equity by 90,750,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs250.70 Million | +10.82% |
| Share Repurchases | Rs27.05 Million | -1.17% |
| Share Issuances | Rs27.05 Million | +1.17% |
| Other Comprehensive Income | Rs-37.73 Million | -1.63% |
| Other Changes | Rs90.75 Million | +3.92% |
| Total Change | Rs- | 15.08% |
Book Value vs Market Value Analysis
This analysis compares BALAXI PHARMACEUTICALS LIMITED's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 186.51x to 0.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-03-31 | Rs0.14 | Rs26.63 | x |
| 2014-03-31 | Rs0.15 | Rs26.63 | x |
| 2015-03-31 | Rs0.01 | Rs26.63 | x |
| 2016-03-31 | Rs0.01 | Rs26.63 | x |
| 2017-03-31 | Rs7.76 | Rs26.63 | x |
| 2018-03-31 | Rs0.30 | Rs26.63 | x |
| 2019-03-31 | Rs0.67 | Rs26.63 | x |
| 2020-03-31 | Rs5.27 | Rs26.63 | x |
| 2021-03-31 | Rs12.34 | Rs26.63 | x |
| 2022-03-31 | Rs21.49 | Rs26.63 | x |
| 2023-03-31 | Rs34.72 | Rs26.63 | x |
| 2024-03-31 | Rs38.23 | Rs26.63 | x |
| 2025-03-31 | Rs41.92 | Rs26.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BALAXI PHARMACEUTICALS LIMITED utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.82%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.68%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 1.34x
- Recent ROE (10.82%) is below the historical average (16.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 5.88% | 51.33% | 0.07x | 1.65x | Rs-309.88K |
| 2014 | 14.05% | 56.78% | 0.16x | 1.54x | Rs315.65K |
| 2015 | 317.43% | 82.71% | 3.36x | 1.14x | Rs991.30K |
| 2016 | -255.26% | -169.17% | 1.33x | 1.13x | Rs-835.21K |
| 2017 | -33.47% | 0.00% | -0.24x | 1.09x | Rs-10.25 Million |
| 2018 | -49.65% | 0.00% | 0.00x | 1.08x | Rs-9.27 Million |
| 2019 | 55.84% | 14.46% | 2.23x | 1.73x | Rs16.14 Million |
| 2020 | 22.00% | 13.38% | 1.27x | 1.30x | Rs33.29 Million |
| 2021 | 58.69% | 16.49% | 2.32x | 1.53x | Rs316.39 Million |
| 2022 | 42.11% | 17.06% | 1.58x | 1.56x | Rs363.41 Million |
| 2023 | 25.13% | 13.66% | 1.40x | 1.31x | Rs276.75 Million |
| 2024 | -1.19% | -0.99% | 0.93x | 1.28x | Rs-225.23 Million |
| 2025 | 10.82% | 8.68% | 0.93x | 1.34x | Rs18.97 Million |
Industry Comparison
This section compares BALAXI PHARMACEUTICALS LIMITED's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,262,772,375
- Average return on equity (ROE) among peers: 7.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BALAXI PHARMACEUTICALS LIMITED (BALAXI) | Rs2.38 Billion | 5.88% | 0.35x | $15.90 Million |
| Blue Jet Healthcare Limited (BLUEJET) | $6.81 Billion | 23.48% | 0.26x | $833.96 Million |
| Concord Biotech Limited (CONCORDBIO) | $11.03 Billion | 15.86% | 0.19x | $1.29 Billion |
| Dishman Carbogen Amcis Limited (DCAL) | $55.49 Billion | 0.32% | 0.56x | $310.59 Million |
| Lyka Labs Limited (LYKALABS) | $-151.11 Million | 0.00% | 0.00x | $23.04 Million |
| SMS Lifesciences India Limited (SMSLIFE) | $1.94 Billion | 4.70% | 1.02x | $42.13 Million |
| Supriya Lifescience Limited (SUPRIYA) | $6.16 Billion | 24.66% | 0.19x | $604.83 Million |
| Take Solutions Limited (TAKE) | $20.00 Million | 0.00% | 0.50x | $67.51 Million |
| Zota Health Care LImited (ZOTA) | $803.57 Million | -7.18% | 0.97x | $430.12 Million |
About BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. The company offers pharmaceutical products across various therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes. The company was fo… Read more